Get to know Khari Lee, ‘Hard Knocks’ star

SHARE Get to know Khari Lee, ‘Hard Knocks’ star
SHARE Get to know Khari Lee, ‘Hard Knocks’ star

The Bears traded a 2017 sixth-round pick to the Houston Texans for undrafted tight end Khari Lee.

The Bears cut tight end Blake Annen as a result of the trade, but Lee will still have to compete for a roster slot behind Martellus Bennett, Zach Miller, Dante Rosario and Bear Pascoe.

It’s uncommon, but there’s no indication if the Bears will keep all five tight ends.

[nicelink url=https://twitter.com/adamjahns/status/639113861069537284]

So who is Khari Lee?

Lee, 6-4 and 235 pounds, was a undrafted free agent from Bowie State University, and starred in the HBO series, “Hard Knocks.”

In the latest episode, Lee impersonated Texans head coach Bill O’Brien, and he had the whole team cracking up.

Before becoming an undrafted free agent, Lee caught 34 passes for 389 yards and a touchdown last season at Bowie State. Lee said he was cut from his freshman high school football team in Baltimore, walked-on to Bowie State and created a drive that helped him exceed to the NFL.

During his three preseason games with the Texans, Lee caught five passes for 71 yards.

The Latest
Link gave his testimony in the trial of businessman James T. Weiss, who is accused of bribing Link and former state Rep. Luis Arroyo. Arroyo has pleaded guilty to the scheme and is serving a nearly five-year prison sentence.
The pieces speak for themselves, and the group performs best when they adopt a pithy approach.
For some primary healthcare providers, the annual physical is an overall assessment of health and a chance to reconnect with the patient, take stock of the previous year, assess any changes and set new goals and plans for the future.
Schools CEO Pedro Martinez says “the pandemic caused a lot of challenges for our city and our district,” particularly for this year’s graduating seniors, who were high school freshmen when schools shut down.
Improved screening is important, and the treatment for latent TB has made great strides, a biotech firm director writes.